STUMP un“stumped”: anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion

@inproceedings{Subbiah2015STUMPUA,
  title={STUMP un“stumped”: anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion},
  author={Vivek Subbiah and Caitlin R McMahon and Shreyaskumar Patel and Ralph G. Zinner and Elvio Gilberto da Silva and Julia A Elvin and Ishwaria Mohan Subbiah and Chimela Ohaji and Dhakshina Moorthy Ganeshan and Deepa Anand and Charles F. Levenback and Jenny Berry and Tim P Brennan and Juliann Chmielecki and Zachary R. Chalmers and John D Mayfield and Vincent A. Miller and Philip J. Stephens and Jeffrey S. Ross and Siraj M Ali},
  booktitle={Journal of hematology & oncology},
  year={2015}
}
BACKGROUND Recurrent, metastatic mesenchymal myxoid tumors of the gynecologic tract present a management challenge as there is minimal evidence to guide systemic therapy. Such tumors also present a diagnostic dilemma, as myxoid features are observed in leiomyosarcomas, inflammatory myofibroblastic tumors (IMT), and mesenchymal myxoid tumors. Comprehensive genomic profiling was performed in the course of clinical care on a case of a recurrent, metastatic myxoid uterine malignancy (initially… CONTINUE READING